Long-Term Neurocognitive and Psychosocial Outcomes in Pediatric Attention-Deficit/Hyperactivity Disorder Following Sustained Pharmacotherapy: A Comprehensive Review of Current Meta-Analytical Evidence

Objectives: This review investigates the long-term neurocognitive and psychosocial outcomes of sustained pharmacotherapy in pediatric Attention-Deficit/Hyperactivity Disorder (ADHD). The primary goal is to determine whether chronic treatment facilitates neurobiological maturation and functional thriving beyond acute symptom relief. Methods: A systematic synthesis of meta-analyses and large-scale longitudinal cohort studies from recent years was conducted. The review focused on developmental trajectories, psychosocial outcomes, and physiological effects of ADHD pharmacotherapy, drawing on evidence from both clinical trials and population-based registries. Findings: Evidence suggests that sustained treatment acts as a catalyst for “neuro-normalization,” supporting structural maturation of the basal ganglia and enhanced white matter connectivity. Psychosocially, consistent adherence is a potent protective factor, significantly reducing the risks of criminal convictions and accidental injuries. Early intervention stabilizes developmental trajectories during critical periods. While improvements in behavioral productivity are more pronounced than gains in long-term academic performance, cumulative evidence indicates that persistent pharmacotherapy effectively buffers against major social and physical morbidities, particularly when maintained through late adolescence. Conclusions: Long-term ADHD management provides a vital physiological foundation for development but remains a dynamic process dependent on treatment continuity. Optimal outcomes require a holistic approach that integrates medical intervention with innovative monitoring technologies and intensive family-based support to safeguard the future potential of neurodivergent youth.